We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0HMP market cap is 23.54M. The company's latest EPS is USD -2.0559 and P/E is -0.05.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.88M | -17.47M | -26.28M | -20.16M | -22.38M |
| Net Income | 2.81M | -13.27M | -24.73M | -17.76M | -19.83M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 18.36M | 13.11M | 50.24M | 26.88M | 7.94M |
| Total Liabilities | 14.5M | 9.52M | 11.99M | 5.26M | 5.4M |
| Total Equity | 3.86M | 3.59M | 38.25M | 21.62M | 2.53M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -15.5M | -12.94M | -19.88M | -22.82M | -17.77M |
| Investing | 3M | N/A | N/A | N/A | N/A |
| Financing | 166k | 6.17M | 57.57M | N/A | -40k |
| Market Cap | 23.54M |
| Price to Earnings Ratio | -0.05 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.14 |
| Price to Book Ratio | 0.38 |
| Dividend Yield | - |
| Shares Outstanding | 9.65M |
| Average Volume (1 week) | 2.3k |
| Average Volume (1 Month) | 6.15k |
| 52 Week Change | 0.00% |
| 52 Week High | 2.44 |
| 52 Week Low | 2.44 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Bellerophon Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.bellerophon.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
